"HEMP STEEL REBARS... Stronger Than Steel?"

Researchers from Rensselaer Polytechnic Institute,confirm that hemp rebar could be a suitable alternative to steel in cement construction.

Dan Walczyk, director of the manufacturing innovation center and Alex Tsamis, associate director of the Architecture Science & Ecology Center, say they have produced an alternative to steel in concrete buildings and various infrastructure projects.

Both scientists agree that hemp-based natural fiber-reinforced thermoplastic rebar has the potential to displace steel as the most preferred reinforcing technology in a few years. These hemp rebars are partially guaranteed to eliminate corrosion challenges, and they are more durable than steel bars.

Rebar is a crucial component in the frameworks of cement buildings. They help construct perfectly standing and durable skeletal frameworks for convention infrastructure projects. On its own, concrete lacks tensile strength, and this is the primary reason why rebars are used—to provide tensile strength.

The Manufacturing Potential of Hemp

About 150 years ago, before the onset of cannabis prohibition and the criminalization of offenders, hemp was used to produce over 75% of the goods consumed by Americans. The manufacturing of hemp-derived goods was scrapped when the government banned the cultivation and usage of the drug based on the threat of abuse. Currently, hemp is at the forefront of manufacturing discussions due to its undeniable potential to serve humans and the global ecosystem.

"Cannabidiol as effective as antipsychotic meds with fewer side effects".

Schizophrenia is a mental disorder that affects a person’s ability to think, feel, and behave clearly. 

It can cause psychotic episodes, and treatment is usually lifelong and involves antipsychotic medications with toxic side effects.

In 2012, researchers published a study in Translational Psychiatry showing that a CBD isolate can treat schizophrenia as effectively as antipsychotic pharmaceuticals — and with far fewer side effects.

In this study, researchers led by Markus Leweke, MD, of the University of Cologne in Germany recruited 39 people with schizophrenia who were hospitalized for a psychotic episode.